Company intelligence / Profile preview

SCARLETRED

Ownership: Private
Employees: ~17
Development stage: Other

Overview

SCARLETRED’s core product—the Scarletred® Vision platform—is CE-certified and commercially available since 2015. It enables standardized remote skin imaging and AI-powered analysis for clinical trials and routine care. The company’s recombinant human superoxide dismutase biologic is under clinical development targeting chronic wounds and radiation/thermal injury protection.

Therapeutic areas: Dermatology
Modalities: DeviceSoftware as a Medical Device (SaMD)Biologic
Industry: Biotech

Beyond the preview

Go deeper on SCARLETRED.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCARLETRED.

Explore the full profile